Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics and obesity: common gene variants influence weight loss response of the norepinephrine/dopamine transporter inhibitor GW320659 in obese subjects.

Pharmacogenetics and genomics - 1 Dec 2005

Spraggs Colin F, Pillai Sreekumar G, Dow David, Douglas Christal, McCarthy Linda, Manasco Penelope K, Stubbins Michael, Roses Allen D

Abstract excerpt

BACKGROUND: GW320659, a highly selective neuronal norepinephrine and dopamine re-uptake inhibitor, has been evaluated for the treatment of obesity. Scrutiny of the weight loss data from a phase II study (GlaxoSmithKline study OBS20001) showed a wide variation in weight loss response following GW320659 treatment and the possibility that the study population might include subgroups with enhanced weight loss...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Body Weight

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dopamine Plasma Membrane Transport Proteins

Share to Double-Blind Method

Share to Drug Administration Schedule

Share to Membrane Transport Proteins

Share to Norepinephrine Plasma Membrane Transport Proteins

Share to Weight Loss

Source

Identifiers

PMID: 16272960
DOI: 10.1097/01213011-200512000-00006

Genes

GRIN1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics and obesity: common gene variants influence weight loss response of the norepinephrine/dopamine transporter inhibitor GW320659 in obese subjects.PMID 16272960Read ↗

A controlled pharmacogenetic trial of sibutramine on weight loss and body composition in obese or overweight adults.Semantic proximity Read ↗

A meta-analysis of potential genetic factors associated with antipsychotic-induced weight gain in adults with severe mental illness.Semantic proximity Read ↗

Comparative physiogenomic analyses of weight loss in response to 2 modes of bariatric surgery: demonstration with candidate neuropsychiatric and cardiometabolic genes.Semantic proximity Read ↗

Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain.Semantic proximity Read ↗

Influence of BMI-associated genetic variants and metabolic risk factors on weight loss with semaglutide: a longitudinal clinico-genomic cohort studySemantic proximity Read ↗

Pharmacogenetics of obesity drug therapy.Semantic proximity Read ↗

Association of orexin receptor polymorphisms with antipsychotic-induced weight gain.Semantic proximity Read ↗

Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications.Semantic proximity Read ↗

Weight change, genetics and antiepileptic drugs.Semantic proximity Read ↗

Pilot study of the G-protein beta3 subunit gene (C825T) polymorphism and clinical response to olanzapine or olanzapine-related weight gain in persons with schizophrenia.Semantic proximity Read ↗

Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis.Semantic proximity Read ↗

Pharmacogenetic Aspects of Antipsychotic Drug-induced Weight Gain - A Critical ReviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.